Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study

ARPINO, GRAZIA
;
BRUZZESE, DARIO;DE LAURENTIIS, MICHELINO;GIULIANO, MARIO;DE PLACIDO, SABINO
2016

Abstract

Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC.
File in questo prodotto:
File Dimensione Formato  
art%3A10.1007%2Fs00432-015-2033-z-2.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Documento in Pre-print
Licenza: Dominio pubblico
Dimensione 937.03 kB
Formato Adobe PDF
937.03 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/615100
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 12
social impact